Takeda Terminates Collaboration Deal With Finch

Takeda Pharmaceutical has ended a collaboration deal with Finch Therapeutics over two inflammatory bowel disease drugs and is returning the development and commercial rights to Finch for two investigational drugs, FIN-524 and FIN-525.

The two product candidates are composed of bacterial strains selected for their potential immuno-modulatory properties. FIN-524 is an investigational treatment for ulcerative colitis while FIN-525 is for treatment of Crohn’s disease.

The two companies entered into the collaboration agreement in April 2017. Effective Nov. 17, Finch will regain worldwide rights to the two investigational products and any other microbiome product candidates for inflammatory bowel disease.